Sanofi loses preemption argument ahead of cancer drug Taxotere bellwether trial
New Delhi: Federal law does not shield Sanofi from a woman's claim that it failed to warn her that its cancer drug Taxotere could cause permanent hair loss, a federal court has ruled, a victory for the plaintiff in the second bellwether trial scheduled in a multidistrict litigation over the drug.Read also: Sanofi wins EU approval for Dupixent for atopic dermatitis in childrenU.S. District...
New Delhi: Federal law does not shield Sanofi from a woman's claim that it failed to warn her that its cancer drug Taxotere could cause permanent hair loss, a federal court has ruled, a victory for the plaintiff in the second bellwether trial scheduled in a multidistrict litigation over the drug.
Read also: Sanofi wins EU approval for Dupixent for atopic dermatitis in children
U.S. District Judge Jane Triche Milazzo in New Orleans on Friday rejected Sanofi's argument that it could not have revised its FDA-approved label, which did not warn of permanent hair loss, at the time of plaintiff Elizabeth Kahn's Taxotere treatment in 2008.
Read also: Sanofi, GSK delay Covid vaccine program to improve immune response
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd